mk-7655 and Sepsis

mk-7655 has been researched along with Sepsis* in 1 studies

Other Studies

1 other study(ies) available for mk-7655 and Sepsis

Article	Year
Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. Diagnostic microbiology and infectious disease, 2021, Volume: 100, Issue:4 Bloodstream infections (BSI) are often caused by drug-resistant pathogens, and novel antimicrobials are needed. We examined the activity of imipenem/relebactam against BSI pathogens from US and Canada: >99% of non-Morganellaceae Enterobacterales, including 100% of MDR isolates, and >94% of Pseudomonas aeruginosa were imipenem/relebactam-susceptible. Imipenem/relebactam could provide an important treatment option. Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Canada; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sepsis; United States	2021

Article

Year

Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019.

Diagnostic microbiology and infectious disease, 2021, Volume: 100, Issue:4

Bloodstream infections (BSI) are often caused by drug-resistant pathogens, and novel antimicrobials are needed. We examined the activity of imipenem/relebactam against BSI pathogens from US and Canada: >99% of non-Morganellaceae Enterobacterales, including 100% of MDR isolates, and >94% of Pseudomonas aeruginosa were imipenem/relebactam-susceptible. Imipenem/relebactam could provide an important treatment option.

Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Canada; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sepsis; United States

2021